改变指南的力量——近20年中国缺血性脑血管病重磅临床研究

doi:10.3969/j.issn.1673-5765.2025.05.002

摘要/Abstract

摘要： 过去20年，中国脑血管病临床研究取得了显著进步，逐步从依赖国外研究成果向以中国学者为主导的国际化研究模式转变。CHANCE研究标志着这一进步的起点，随着其他标志性研究的推出，中国逐渐在全球脑血管病研究领域占据重要地位，一系列中国临床研究直接改写了国内外脑血管病相关诊疗指南。本文回顾中国近20年缺血性脑血管病领域的重要临床研究，探讨其改变指南的循证依据，并展望未来研究方向，以期进一步推动中国缺血性脑血管病临床研究的高质量发展。

关键词: 缺血性脑血管病; 临床研究; 指南; 中国

Abstract: Over the past two decades, China has made remarkable strides in clinical research on cerebrovascular disease, gradually shifting from relying on foreign research achievements to an international research model led by Chinese researchers. The CHANCE study marks the starting point of this progress, and with the introduction of other landmark studies, China has increasingly gained prominence in the global cerebrovascular disease research community. A series of key Chinese clinical studies have directly revised both national and international cerebrovascular disease guidelines. This article reviews the important clinical studies on ischemic cerebrovascular disease in China over the past two decades, explores the evidence-based basis for changing guidelines, and discusses future research directions, aiming to further advance the high-quality development of clinical research on ischemic cerebrovascular disease in China.

Key words: Ischemic cerebrovascular disease; Clinical research; Guideline; China

中图分类号:

谭泽锋, 徐安定. 改变指南的力量——近20年中国缺血性脑血管病重磅临床研究[J]. 中国卒中杂志, 2025, 20(5): 529-548.

TAN Zefeng, XU Anding. The Power of Changing Guidelines: Two Decades of Key Clinical Trials on Ischemic Cerebrovascular Disease in China[J]. Chinese Journal of Stroke, 2025, 20(5): 529-548.

参考文献

[1] 饶明俐. 《中国脑血管病防治指南》摘要（一）[J]. 中风与神经疾病杂志，2005，22（5）：388-393.
RAO M L. Abstract（Ⅰ）of guidelines for the prevention and treatment of cerebrovascular diseases in China[J]. J Apoplexy and Nervous Diseases，2005，22（5）：388-393.
[2] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J/OL]. N Engl J Med，2013，369：11-19[2025-01-10]. https://doi.org/10.1056/NEJMoa1215340.
[3] WANG Y J，CUI L Y. JI X M，et al. The China national stroke registry for patients with acute cerebrovascular events：design，rationale，and baseline patient characteristics[J]. Int J Stroke，2011，6（4）：355-361.
[4] LI Z X，WANG C J，ZHAO X Q，et al. Substantial progress yet significant opportunity for improvement in stroke care in China[J]. Stroke，2016，47（11）：2843-2849.
[5] WANG Y J，JING J，MENG X，et al. The third China national stroke registry（CNSR-Ⅲ）for patients with acute ischaemic stroke or transient ischaemic attack：design，rationale and baseline patient characteristics[J]. Stroke Vasc Neurol，2019，4（3）：158-164.
[6] 中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010[J]. 中华神经科杂志，2010，43（2）：154-160.
Writing Group of Secondary Prevention Guideline for Ischemic Stroke，Chinese Society of Neurology，Chinese Stroke Society. Guideline for secondary prevention of ischemic stroke and transient ischemic attack in China 2010[J]. Chin J Neurol，2010，43（2）：154-160.
[7] CHENG S，XU Z，BIAN S Z，et al. The STROMICS genome study：deep whole-genome sequencing and analysis of 10 k Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay
[J/OL]. Cell Discov，2023，9（1）：75[2025-01-10]. https://doi.org/10.1038/s41421-023-00582-8.
[8] WANG W Z，JIANG B，SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017，135（8）：759-771.
[9] 王伊龙，赵性泉，刘新峰，等. 高危非致残性缺血性脑血管事件诊疗指南[J]. 中国卒中杂志，2016，11（6）：481-491.
WANG Y L，ZHAO X Q，LIU X F，et al. Guideline for management of patients with high-risk non-disabling ischemic cerebrovascular events[J]. Chin J Stroke，2016，11（6）：481-491.
[10] JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[11] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
[12] GAO Y，CHEN W Q，PAN Y S，et al. Dual antiplatelet treatment up to 72 hours after ischemic stroke[J]. N Engl J Med，2023，389（26）：2413-2424.
[13] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[14] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[15] Intercollegiate Stroke Working Party. National clinical guideline for stroke for the UK and Ireland[EB/OL].（2023-05-04）[2025-01-10]. https://www.strokeguideline.org.
[16] ALAMOWITCH S，TURC G，PALAIODIMOU L，et al. European Stroke Organisation（ESO）expedited recommendation on tenecteplase for acute ischaemic stroke[J]. Eur Stroke J，2023，8（1）：8-54.
[17] 中国卒中学会. 中国脑血管病临床管理指南[M]. 2版. 北京：人民卫生出版社，2023.
Chinese Stroke Association. Chinese Stroke Association guidelines for clinical management of cerebrovascular diseases[M]. 2nd ed. Beijing：People’s Medical Publishing House，2023.
[18] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[19] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[20] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[21] SONG H Q，WANG Y，MA Q F，et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset：a phase 3 randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（7）：e2325415[2025-01-10]. https://doi.org/10.1001/jamanetworkopen.2023.25415.
[22] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label，non-inferiority，randomised controlled trial[J]. Lancet Neurol，2025，24（1）：33-41.
[23] 中国卒中学会，《中国卒中学会急性缺血性卒中再灌注治疗指南》编写组. 中国卒中学会急性缺血性卒中再灌注治疗指南2024[J]. 中国卒中杂志，2024，19（12）：1460-1478.
Chinese Stroke Association，Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke. Chinese Stroke Association guidelines on reperfusion therapy for acute ischemic stroke 2024[J]. Chin J Stroke，2024，19（12）：1460-1478.
[24] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[25] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[26] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[27] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[28] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[29] 中国卒中学会，中国卒中学会神经介入分会，中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志，2023，18（6）：684-711.
Chinese Stroke Association，Chinese Interventional Neuroradiology Society，Intervention Group of Committee of Stroke Prevention and Control of Chinese Preventive Medicine Association. Chinese guideline for endovascular treatment of acute ischemic stroke 2023[J]. Chin J Stroke，2023，18（6）：684-711.
[30] STRBIAN D，TSIVGOULIS G，OSPEL J，et al. European Stroke Organisation（ESO）and European Society for Minimally Invasive Neurological Therapy（ESMINT）guideline on acute management of basilar artery occlusion[J/OL]. J Neurointerv Surg，2024，16（9）：e7[2025-01-10]. https://doi.org/10.1136/jnis-2024-022053.
[31] MAJOIE C B，CAVALCANTE F，GRALLA J，et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke：individual participant data meta-analysis of six randomised trials[J]. Lancet，2023，402（10406）：965-974.
[32] QIU Z M，LI F L，SANG H F，et al. Effect of intravenous tirofiban vs. placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke：the RESCUE BT randomized clinical trial[J]. JAMA，2022，328（6）：543-553.
[33] ZI W J，SONG J X，KONG W L，et al. Tirofiban for stroke without large or medium-sized vessel occlusion[J]. N Engl J Med，2023，388（22）：2025-2036.
[34] GAO P，WANG T，WANG D M，et al. Effect of stenting plus medical therapy vs. medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis：the CASSISS randomized clinical trial[J]. JAMA，2022，328（6）：534-542.
[35] SUN X，DENG Y M，ZHANG Y，et al. Balloon angioplasty vs. medical management for intracranial artery stenosis：the BASIS randomized clinical trial[J]. JAMA，2024，332（13）：1059-1069.
[36] HE J，ZHANG Y H，XU T，et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke：the CATIS randomized clinical trial[J]. JAMA，2014，311（5）：479-489.
[37] WARNER J J，HARRINGTON R A，SACCO R L，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke[J]. Stroke，2019，50（12）：3331-3332.
[38] SANDSET E C，ANDERSON C S，BATH P M，et al. European Stroke Organisation（ESO）guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage[J/OL]. Eur Stroke J，2021，6（2）：Ⅱ[2025-01-10]. https://doi.org/10.1177/23969873211026998.
[39] LIU L P，XIE X W，PAN Y S，et al. Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke：multicentre，open label，randomised，controlled trial[J/OL]. BMJ，2023，383：e076448
[2025-01-03]. https://doi.org/10.1136/bmj-2023-076448.
[40] XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.
[41] FU Y，WANG A X，TANG R H，et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke：the TASTE-SL randomized clinical trial[J]. JAMA Neurol，2024，81（4）：319-326.
[42] WANG C J，GU H Q，DONG Q，et al. Rationale and design of treatment of acute ischaemic stroke with edaravone dexborneol Ⅱ（TASTE-2）：a multicentre randomised controlled trial[J]. Stroke Vasc Neurol，2024，9（6）：730-737.
[43] WANG A X，JIA B X，ZHANG X L，et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke：a randomized clinical trial[J]. JAMA Neurol，2023，80（8）：851-859.
[44] LI G，LIN Y P，YANG J，et al. Intensive ambulance-delivered blood-pressure reduction in hyperacute stroke[J]. N Engl J Med，2024，390（20）：1862-1872.
[45] KERNAN W N，OVBIAGELE B，BLACK H R，et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke，2014，45（7）：2160-2236.
[46] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. 2018 guidelines for the early management of patients with acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association
[J/OL]. Stroke，2018，49（3）：e46-e110[2025-01-10].
https://doi.org/10.1161/STR.0000000000000158.
[47] BOULANGER J M，LINDSAY M P，GUBITZ G，et al. Canadian stroke best practice recommendations for acute stroke management：prehospital，emergency department，and acute inpatient stroke care，6th edition，update 2018[J]. Int J Stroke，2018，13（9）：949-984.
[48] PRASAD K，SIEMIENIUK R，HAO Q K，et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke：a clinical practice guideline[J/OL]. BMJ，2018，363：k5130[2025-01-10]. https://doi.org/10.1136/bmj.k5130.
[49] FONSECA A C，MERWICK Á，DENNIS M，et al. European Stroke Organisation（ESO）guidelines on management of transient ischaemic attack[J/OL]. Eur Stroke J，2021，6（2）：163-186. [2025-01-10]. https://doi.org/10.1177/2396987321992905.
[50] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association
[J/OL]. Stroke，2021，52（7）：e364-e467[2025-01-10].
https://doi.org/10.1161/STR.0000000000000375.
[51] LEE C R，LUZUM J A，SANGKUHL K，et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy：2022 update[J]. Clin Pharmacol Ther，2022，112（5）：959-967.